Related references
Note: Only part of the references are listed.Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
CT of colon cancer metastases to the liver using modified RECIST criteria: Determining the ideal number of target lesions to measure
TT Zacharia et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2006)
A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response
M Mazumdar et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
